FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation

Blood

Volumn 87, Issue 8, 1996, Pages 3514-3519

  Fay, Joseph W ^a   Wingard, John R ^b   Antin, Joseph H ^b   Collins, Robert H ^b   Piñeiro, Luis A ^b   Blazar, Bruce R ^b   Saral, Rein ^b   Bierer, Barbara E ^b   Przepiorka, Donna ^b   Fitzsimmons, William E ^b   Maher, Rochelle M ^b   Weisdorf, Daniel J ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEVER; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEADACHE; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MYELODYSPLASIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

EID: 15844395463     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.8.3514.bloodjournal8783514     Document Type: Article

References (48)

1. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
2. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M, Appelbaum FR, Bensinger WI, Buckner CD, Clift RA, Doney K, Fefer A, McGuffin R, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP: Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65:1325, 1985
3. Ringden O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg JH, Dicke K, Masaoka T, Powles RL, Rimm AA, Rozman C, Sobocinski KA, Speck B, Zwaan FE, Bortin MM: Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical Sibling bone marrow transplants for early leukemia. Blood 81:1094, 1993
4. Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, Cheever MA, Clift RA, Doney KC, Flournoy N, Kennedy MS, Loughran TP, McGuffin RW, Sale GE, Sanders JE, Singer JW, Stewart PS, Sullivan KM, Witherspoon RP: Marrow transplantation for chronic myelocytic leukemia: A controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease Blood 66:698, 1985
5. Irle D, Deeg HJ, Buckner CD, Kennedy M, Clift R, Storb R, Appelbaum FR, Beatty P, Bensinger W, Doney K, Cheever M, Fefer A, Greenberg P, Hill R, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res 9:1255, 1985
6. Ringden O, Backman L, Lonnqvist B, Heimdahl A, Lindholm A, Bolme P, Gahrton G: A randomized trial comparing use of cyclosporine and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematologic malignancies. Bone Marrow Transplant 1:41, 1986
7. Biggs JC, Atkinson K, Gillett E, Downs K, Concannon A, Dodds A: A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation. Transplant Proc 18:253, 1986
8. Aschan J, Ringden O, Sundberg B, Gahrton G, Ljungman, Winiarski J: Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 7.113, 1991
9. Morishima Z, Morishita Z, Tanimoto M, Ohno R, Saito H, Horibe K, Hamajima N, Naito K, Yamada K, Yokomaku S, Hirabayashi N, Yamada H, Nakaide Y, Kojima S, Minami S, Matsuyama K, Kodera Y, Nagoya Bone Marrow Transplantation Group: Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homogeneity. Blood 74:2252, 1989
10. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225, 1993
11. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, Hill R, Longton G, Lum L, Martin P, McGuffin R, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68:119, 1986
12. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE: Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation 52:590, 1991
13. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE: FK506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery 110:357, 1991
14. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Fitzsimmons W, Graham TC, Pepe M, Pettinger M, Sale G, van der Jagt R, Schuening FG: FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 56:800, 1993
15. Arai K, Hotokebuchi T, Miyahara H, Arita C, Montai M, Sugioka Y, Kaibara N: Prolonged limb allograft survival with short-term treatment with FK506 in rats. Transplant Proc 21:2191, 1989
16. Murase N, Demetris AJ, Matsuzaki T, Yagihashi A, Todo S, Fung J, Starzl TE: Long survival in rats after multivisceral versus isolated small bowel allotransplantation under FK506. Surgery 110:87, 1991
17. Yoshima F, Nakamura K, Zhu Y, Suzuki M, Funakoshi Y, Carrieri G, Wu Y, Furukawa H, Demetris AJ, Todo S, Starzl TE: Canine total orthotopic small bowel transplantation under FK506. Transplant Proc 23:3240, 1991
18. Masaoka T, Shibata H, Kakishita, Kanamaru A, Takemoto Y, Moriyama Y: Phase II study of FK506 for allogeneic bone marrow transplantation. Transplant Proc 23:3228, 1991
19. Tzakis AG, Abu-Elmagd K, Fung JJ, Bloom EJ, Nour B, Greif F, Starzl TE: FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 23:3225, 1991
20. Bloom EJ, Abu-Elmagd K, Barnes J, Silverman M, Ball E, Pincus S, Rybka WB, Starzl TE, Fung JJ. Use of FK506 for graft-versus-host disease (GVHD) following bone marrow transplantation (BMT). J Cell Biochem 18:90, 1994 (suppl B)
21. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK506 for liver, kidney and pancreas transplantation. Lancet 2:1000, 1989
22. Klintmalm GBG, Goldstein R, Gonwa T, Wiesner RH, Krom RAF, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, Busuttil RW, McDiarmid S, Esquivel CO, Nakazato P, Marsh JW, Woodle ES, Kalayoglu M, D'Alessandro AM, Pirsch JD, Miller C, Schwartz M, Lewis WD, Monaco AP, Jenkins RL, Emond JC, Thistlethwaite JR, Whitington PF, Steinmuller DR, Fitzsimmons WE, Lawrence I: Use of FK506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. U.S. Multicenter FK506 Liver Study Group. Transplant Proc 25:635, 1993
23. Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Darras FS, Carrieri G, McCauley J, Demetris AJ, Randhawa P, Jensen C, Hakala TR, Fung JJ, Starzl TE: FK506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 25:638, 1993
24. The US Multicenter FK56 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110, 1994
25. European FK506 Multicentre Liver Study Group: Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 344:423, 1994
26. Tamura K, Kobayashi M, Hashimoto K, Kojima K, Nagase K, Iwasaki K, Kaizu T, Tanaka H, Niwa M: A highly sensitive method to assay FK506 levels in plasma. Transplant Proc 19:23, 1987
27. Cadoff EM, Venkataramanan R, Krajack A, Jain AS, Fung JJ, Todo S, Starzl TE. Assay of FK506 in plasma. Transplant Proc 22:50, 1990
28. Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, Shoemaker K, Kobayashi M: A whole blood FK506 assay for the IMx analyzer. Transplant Proc 23:2748, 1991
29. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone Marrow Transplantation (second of two parts). N Engl J Med 292:895, 1975
30. Sullivan K, Witherspoon R, Storb R, Appelbaum FR, Beatty P, Bensinger W, Bigelow C, Buckner CD, Cheever M, Clift RA, Doney K, Fefer A, Greenberg P, Hansen J, Martin P, Matthews D, McDonald G, Meyers J, Petersen FB, Sanders J, Shulman H, Singer J, Stewart P, Thomas ED: Chronic graft-versus-host disease: Pathogenesis, diagnosis, treatment, and prognostic factors, in Baum SJ, Santos GW, Takaku F, (eds): Recent Advances and Future Directions in Bone Marrow Transplantation. New York, NY, Springer-Verlag, 1988, p 150
31. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK506, a novel immunosuppressant isolated from a Streptomyces I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 40:1249, 1987
32. Zeevi A, Eiras G, Bach FH, Fung JJ, Todo S, Starzl T, Duquesnoy RJ: Functional differentiation of human cytotoxic T lymphocytes in the presence of FK506 and CyA. Transplant Proc 22:106, 1990
33. Kay JE, Moore AL, Doe SEA, Benzie CR, Schonbrunner R, Schmid FX, Halestrap AP: The mechanism of action of FK506. Transplant Proc 22:96, 1990
34. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochia T: FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibtot 40:1256, 1987
35. Vogelsang GB, Hess AD: Graft-versus-host disease: New directions for a persistent problem. Blood 84:2061, 1994
36. Bierer BE, Schreiber SL, Burakoff SJ: The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol 21:439, 1991
37. Jiang H, Suguo H, Takahara S, Takano Y, Li D, Kameoka H, Moutabarri A, Kokado Y, Ishibashi M, Okuyama A, Sonoda T: Combined immunosuppressive effect of FK506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. Transplant Proc 2:2933, 1991
38. Chen-Woan M, Zerbe TR, Zeevi A, Kaufman C, Mallick C, Warty VJ, Griffith BP, Kormos RL, Armitage J, Duquesnoy RJ: Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK506 immunosuppression. Transplant Proc 23:2941, 1991
39. Kawauchi M, Van Arsdell G, Alonso de Begona J, Gundry SR, Bailey LL, Nehlsen-Cannarella S: Flow cytometric analysis of lymphocyte populations in FK506-treated newborn goats. Transplant Proc 23:2970, 1991
40. Goto T, Kino T, Hatanaka M, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK506: Historical perspectives. Transplant Proc 23:2713, 1991
41. Krochak RJ, Barker DJ: Radiation nephritis: Clinical manifestations and pathophysiologic mechanisms. Urology 27:389, 1986
42. Rabinowe SN, Soiffer RJ, Tarbell NJ, Neuberg D, Freedman AS, Seifter J, Blake KW, Gribben JG, Anderson KC, Takvorian T, Ritz J, Nadler LM: Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologie malignancies. Blood 77:1837, 1991
43. Atkinson K, Biggs JC, Hayes J, Ralston M, Dodds AJ, Concannon AJ, Naidoo D: Cyclosporin A associated nephrotoxicity in the first 100 days post allogeneic bone marrow transplantation: Three distinct syndromes. Br J Haematol 54:59, 1989
44. Ichihashi T, Naoe T, Yoshida H, Kiyoi H, Fukutani H, Kubo K, Yamauchi T, Saito H, Ohno R: Haemolytic-uraemic syndrome during FK506 therapy. Lancet 340:60, 1992
45. Holman MJ, Gonwa TA, Cooper B, Husberg BS, Goldstein RM, Gibbs JF, Klintmalm GB: FK-506 associated thrombotic thrombocytopenic purpura. Transplantation 55:205, 1993
46. Weisdorf D, Haake R, Blazar, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A: Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcomes. Blood 75:1024, 1990
47. Aschan J: Treatment of moderate to severe acute graft-versus-host disease: A retrospective analysis. Bone Marrow Transplant 14:601, 1994
48. Fay JW, Nash RA, Collins RH, Anasetti C, Pineiro L, Storb RF, Aro RM, Fitzsimmons WE: FK506-based immunosuppression for prevention of graft-versus-host disease (GVHD) after unrelated marrow donor (UMD) transplantation. XV World Congress of the Transplantation Society. Kyoto, Japan, 1994, p 84 (abstr)